CAMBRIDGE, Mass. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
CAMBRIDGE, Mass. , March 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
CAMBRIDGE, Mass. , March 14, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
CAMBRIDGE, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
Overview and Update on the Immuno-STAT Platform for Selective Targeting of Tumor-specific T cells CAMBRIDGE, Mass. , May 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively
Initiation of First-in-Human Phase 1 Clinical Trial for Monotherapy Dose Escalation Earns $2.5 Million Milestone for IND Acceptance from Partner LG Chem Life Sciences CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE), an innovative clinical stage immunotherapy
CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. , (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases,
CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic
CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that on September 23, 2019 it